Connect with us

Health

SEROLOGICAL RESPONSES AFTER SARS‐COV‐2 VACCINATION FIRST DOSE IN PATIENTS WITH LYMPHOID MALIGNANCY: FIRST INTERIM ANALYSIS OF THE UK PROSECO STUDY – Wiley

Click on the article title to read more.

Published

on

Article feature image

Introduction: COVID-19 is thought to be more frequent and severe in patients with cancer. Lymphoma patients may be especially vulnerable, due to the immunodeficiency and immune dysregulation caused by the lymphoma itself and the antitumor treatments. This…

Click here to view the original article.

You might also like ...

UK scientists believe it is ‘almost certain’ a coronavirus variant will emerge that beats current vaccines – WTVA
Article feature image
What Kenya needs to do better as it braces for fourth wave of COVID-19 – The Conversation CA